Intech Investment Management LLC lifted its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 276.5% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 46,749 shares of the medical instruments supplier’s stock after acquiring an additional 34,333 shares during the period. Intech Investment Management LLC owned 0.07% of West Pharmaceutical Services worth $17,333,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also modified their holdings of the company. Silver Oak Securities Incorporated raised its stake in West Pharmaceutical Services by 22.4% during the third quarter. Silver Oak Securities Incorporated now owns 1,950 shares of the medical instruments supplier’s stock worth $780,000 after purchasing an additional 357 shares during the period. Bessemer Group Inc. grew its stake in shares of West Pharmaceutical Services by 21.9% in the 3rd quarter. Bessemer Group Inc. now owns 1,189 shares of the medical instruments supplier’s stock valued at $442,000 after buying an additional 214 shares during the period. Harbour Investments Inc. grew its stake in shares of West Pharmaceutical Services by 994.2% in the 3rd quarter. Harbour Investments Inc. now owns 755 shares of the medical instruments supplier’s stock valued at $280,000 after buying an additional 686 shares during the period. Virtus Advisers LLC purchased a new stake in shares of West Pharmaceutical Services in the 3rd quarter valued at approximately $37,000. Finally, Phoenix Financial Ltd. increased its holdings in shares of West Pharmaceutical Services by 23.1% during the 3rd quarter. Phoenix Financial Ltd. now owns 815 shares of the medical instruments supplier’s stock worth $302,000 after buying an additional 153 shares during the last quarter. Hedge funds and other institutional investors own 93.90% of the company’s stock.
West Pharmaceutical Services Stock Down 0.0%
NYSE:WST opened at $416.34 on Monday. The company has a quick ratio of 2.10, a current ratio of 2.82 and a debt-to-equity ratio of 0.07. The stock’s fifty day moving average is $380.32 and its two-hundred day moving average is $320.84. West Pharmaceutical Services, Inc. has a 52 week low of $223.83 and a 52 week high of $438.27. The stock has a market capitalization of $29.00 billion, a price-to-earnings ratio of 46.73, a price-to-earnings-growth ratio of 2.53 and a beta of 1.13.
West Pharmaceutical Services (NYSE:WST – Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The medical instruments supplier reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.20 by $0.46. The business had revenue of $874.50 million during the quarter, compared to analysts’ expectations of $827.12 million. West Pharmaceutical Services had a return on equity of 21.78% and a net margin of 18.81%. The company’s revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the firm posted $1.96 earnings per share. Research analysts anticipate that West Pharmaceutical Services, Inc. will post 9.45 EPS for the current year.
West Pharmaceutical Services Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 18th. Shareholders of record on Wednesday, November 11th will be given a $0.26 dividend. The ex-dividend date of this dividend is Tuesday, November 10th. This represents a $1.04 annualized dividend and a yield of 0.2%. This is an increase from West Pharmaceutical Services’s previous quarterly dividend of $0.22. West Pharmaceutical Services’s dividend payout ratio is presently 11.67%.
Analyst Ratings Changes
Several equities research analysts have issued reports on the company. Barclays raised their target price on West Pharmaceutical Services from $440.00 to $500.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. Zacks Research lowered West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 12th. TD Cowen increased their price target on West Pharmaceutical Services from $420.00 to $500.00 and gave the stock a “buy” rating in a report on Friday, October 30th. UBS Group increased their price target on West Pharmaceutical Services from $340.00 to $415.00 and gave the stock a “buy” rating in a report on Wednesday, September 9th. Finally, Wall Street Zen raised West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research report on Sunday, November 1st. Thirteen equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, West Pharmaceutical Services currently has an average rating of “Moderate Buy” and a consensus price target of $424.67.
Get Our Latest Analysis on West Pharmaceutical Services
Insiders Place Their Bets
In other West Pharmaceutical Services news, VP Annette Favorite sold 8,135 shares of the business’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $340.81, for a total transaction of $2,772,489.35. Following the sale, the vice president directly owned 16,845 shares in the company, valued at $5,740,944.45. This represents a 32.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders sold 15,659 shares of company stock valued at $5,443,749. Insiders own 0.60% of the company’s stock.
West Pharmaceutical Services Profile
West Pharmaceutical Services designs and manufactures packaging components and delivery systems used by the pharmaceutical, biotechnology, and medical device industries. Its products help contain and administer injectable medicines and include elastomeric components, such as stoppers and seals, as well as syringe components and other packaging and delivery solutions. The company also provides contract manufacturing services for medical devices and pharmaceutical delivery systems. Its customers include companies developing and producing branded, generic, and biologic medicines.
Further Reading
- Five stocks we like better than West Pharmaceutical Services
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST – Free Report).
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.
